Alzheimer’s Disease: Choice of Ancillary Treatments

Deadline
Jan 12, 2017
OPPORTUNITY NO.
RFA-AG-17-059
MECHANISM
R21/R33 (also available: R33)
RESEARCH AREA(S)
SYNOPSIS

Multimorbidity in Alzheimer’s Disease Impacts Choice of Ancillary Treatments

This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimer’s disease and related dementia (ADRD). Studies may be observational treatment studies or pragmatic clinical trials.

This FOA will support pilot research to test the feasibility of interventions (R21 phase) that, if successful, can transition to an R33 phase for implementation of pragmatic trials. The transition from the R21 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the criteria that are specified in the R21 phase.

Deadlines:

  • Pre-Application Submission: N/A
  • Application Submission: 5:00 PM local time of applicant organization, Jan. 12, 2017

Companion Opportunity:

ELIGIBILITY

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.